Cipla arm secures marketing rights for cancer drug in US

Updated: Fri, Aug 10, 2018
09:06 pm
PTI
RELATED NEWS
Infosys Chairman Nandan Nilekani on India's Digital Economy I Kotak Institutional Equities highlights details Infosys Chairman Nandan Nilekani on India's Digital Economy I Kotak Institutional Equities highlights details
Digital economy to outpace GDP growth, will result in 'competitive advantage period' for leaders in digital space highlights ICICI Securities Digital economy to outpace GDP growth, will result in 'competitive advantage period' for leaders in digital space highlights ICICI Securities
#GSTMakeItEasy: Facing GST related issues? Big initiative by Zee Business - Tweet your problems now! Check all details here #GSTMakeItEasy: Facing GST related issues? Big initiative by Zee Business - Tweet your problems now! Check all details here

Drug major Cipla today said its subsidiary has secured rights from Hyderabad-based MSN Laboratories to market and distribute colon cancer treatment drug Capecitabine in the US market.

Cipla USA, Inc, a subsidiary of the company will be marketing the drug in strengths of 150 and 500 mg tablets.

The company's product is generic equivalent of Genentech's Xeloda.

Capecitabine tablets are indicated in patients with colon cancer and for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.

As per IQVIA (IMS Health) dat, Xeloda and its generic equivalents had sales of around USD 178 million in the US for 12-month period ending June 2018.

Shares of Cipla today ended 0.27 per cent up at Rs 620.90 on the BSE.

 

(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.